The DOI matches its Crossref record.
Chronic lymphocytic leukemia.
Abstract
Our concept of the pathogenesis of chronic lymphocytic leukemia has undergone remarkable changes during the past decade. This review addresses the latest ideas concerning the origin of this common form of leukemia and discusses how molecular investigations are beginning to change the management of the disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In patients with chronic lymphocytic leukemia (CLL) the characteristic accumulation of monoclonal mature B lymphocytes in the peripheral blood (PB), bone marrow (BM), and secondary lymphoid tissues (SLTs) is mostly attributed to defective in vivo apoptosis, whereas these cells undergo rapid cell death in vitro.1,2”
From RhoH is critical for cell-microenvironment interactions in chronic lymphocytic leukemia in mice and humans (2012) · cites this paper as [1]
In the citing paper
“These and other data suggest that signaling through the BCR plays an important role in CLL pathogenesis(1).”
From Involvement of RhoH GTPase in the development of B-cell chronic lymphocytic leukemia (2010) · cites this paper as [1]
In the citing paper
“BCR signaling has been implicated in the pathogenesis of CLL, and this disease has been hypothesized to be initiated and driven by antigen stimulation (reviewed in(1)).”
From Involvement of RhoH GTPase in the development of B-cell chronic lymphocytic leukemia (2010) · cites this paper as [1]
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 112
- 10.1056/NEJM199510193331606 · DOI
- Dameshek W, 1967, Blood, 29, 566, 10.1182/blood.V29.4.566.566 · DOI
- Patel DV, Rai KR. Chronic lymphocytic leukemia. In: Hoffman R, Benz EJ, Shattil SJ, et al., eds. Hematology, principles and practice. 4th ed. Philadelphia: Elsevier Churchill Livingstone, 2005:1437-54.
- 10.1084/jem.180.1.5 · DOI
- 10.1084/jem.191.3.485 · DOI
- 10.1006/clim.2001.5049 · DOI
- 10.1073/pnas.98.3.1166 · DOI
- 10.1084/jem.20011112 · DOI
- 10.1126/science.1073924 · DOI
- Deaglio S, 1998, J Immunol, 160, 395, 10.4049/jimmunol.160.1.395 · DOI
- Lund FE, 1996, J Immunol, 157, 1455, 10.4049/jimmunol.157.4.1455 · DOI
- Zupo S, 2000, Blood, 95, 1199, 10.1182/blood.V95.4.1199.004k21_1199_1206 · DOI
- 10.1038/nri955 · DOI
- 10.1016/0092-8674(92)90598-7 · DOI
- Matutes E, 1994, Leukemia, 8, 1640
- Moreau EJ, 1997, Am J Clin Pathol, 108, 378, 10.1093/ajcp/108.4.378 · DOI
- Ternynck T, 1974, Blood, 43, 789, 10.1182/blood.V43.6.789.789 · DOI
- Rai KR, 1975, Blood, 46, 219, 10.1182/blood.V46.2.219.219 · DOI
- 10.1002/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO;2-V · DOI
- 10.1016/0167-5699(94)90009-4 · DOI
- 10.1084/jem.181.4.1507 · DOI
- Oscier DG, 1997, Blood, 89, 4153, 10.1182/blood.V89.11.4153 · DOI
- 10.1172/JCI3009 · DOI
- Hamblin TJ, 1999, Blood, 94, 1848, 10.1182/blood.V94.6.1848 · DOI
- Krober A, 2002, Blood, 100, 1410, 10.1182/blood.V100.4.1410.h81602001410_1410_1416 · DOI
- Zupo S, 1996, Blood, 88, 1365, 10.1182/blood.V88.4.1365.bloodjournal8841365 · DOI
- Damle RN, 1999, Blood, 94, 1840, 10.1182/blood.V94.6.1840 · DOI
- 10.1182/blood.V98.1.181 · DOI
- 10.1046/j.1365-2141.2001.03149.x · DOI
- 10.1056/NEJMoa023143 · DOI · Paper page
- 10.1182/blood-2002-06-1683 · DOI · Paper page
- 10.1182/blood-2002-10-3306 · DOI
- 10.1016/S0140-6736(03)15260-9 · DOI · Paper page
- 10.1056/NEJMoa040857 · DOI · Paper page
- 10.1084/jem.194.11.1639 · DOI
- 10.1084/jem.194.11.1625 · DOI
- Maloum K, 2000, Blood, 96, 377, 10.1182/blood.V96.1.377 · DOI
- 10.1182/blood.V99.3.1023 · DOI
- Oscier DG, 2002, Blood, 100, 1177, 10.1182/blood.V100.4.1177.h81602001177_1177_1184 · DOI
- 10.1146/annurev.immunol.21.120601.141018 · DOI
- 10.1182/blood-2003-12-4312 · DOI
- 10.1182/blood.V97.6.1892 · DOI
- 10.1182/blood-2002-06-1801 · DOI
- 10.1016/1074-7613(95)90029-2 · DOI
- 10.1056/NEJM200012283432602 · DOI
- 10.1182/blood.V97.7.2098 · DOI
- 10.1073/pnas.242606799 · DOI · Paper page
- 10.1038/nrg1379 · DOI · Paper page
- 10.1073/pnas.0404432101 · DOI
- 10.1073/pnas.91.26.12530 · DOI
- Narducci MG, 2000, Cancer Res, 60, 2095
- 10.1073/pnas.102181599 · DOI · Paper page
- 10.1182/blood-2003-10-3407 · DOI
- Johnson TA, 1997, J Immunol, 158, 235, 10.4049/jimmunol.158.1.235 · DOI
- Widhopf GF II, 2001, J Immunol, 166, 95, 10.4049/jimmunol.166.1.95 · DOI
- 10.1182/blood-2002-08-2432 · DOI
- 10.1182/blood.V99.6.2262 · DOI
- 10.1182/blood-2002-11-3485 · DOI
- 10.1172/JCI19399 · DOI
- 10.1084/jem.20040544 · DOI
- 10.1182/blood-2004-01-0132 · DOI
- 10.1182/blood-2004-03-0818 · DOI
- 10.1016/0896-8411(88)90068-6 · DOI
- 10.1084/jem.169.1.255 · DOI
- Borche L, 1990, Blood, 76, 562, 10.1182/blood.V76.3.562.562 · DOI
- 10.1016/0167-5699(94)90022-1 · DOI
- Diaw L, 1997, J Immunol, 158, 968, 10.4049/jimmunol.158.2.968 · DOI
- 10.1016/S0167-5699(99)01509-1 · DOI
- 10.1093/intimm/3.9.865 · DOI
- Dameshek W, 1959, Blood, 14, 1151, 10.1182/blood.V14.10.1151.1151 · DOI
- 10.1038/ni1036 · DOI
- 10.1016/j.coi.2004.03.010 · DOI
- 10.1002/eji.1830160821 · DOI
- Karray S, 1987, Blood, 70, 1105, 10.1182/blood.V70.4.1105.1105 · DOI
- Michel F, 1993, J Immunol, 150, 3624, 10.4049/jimmunol.150.8.3624 · DOI
- Lankester AC, 1995, Blood, 86, 1090, 10.1182/blood.V86.3.1090.1090 · DOI
- 10.1182/blood-2001-11-0126 · DOI
- 10.1182/blood-2002-06-1822 · DOI
- 10.1046/j.1365-2141.2002.03759.x · DOI
- 10.1038/sj.leu.2402944 · DOI
- Alfarano A, 1999, Blood, 93, 2327, 10.1182/blood.V93.7.2327 · DOI
- 10.1073/pnas.090087097 · DOI
- Mangiola M, 2003, Leuk Lymphoma, 44, S4
- 10.1182/blood.V98.10.3050 · DOI
- 10.1046/j.1365-2141.1996.00305.x · DOI · Paper page
- 10.1182/blood.V99.3.1030 · DOI · Paper page
- 10.1182/blood-2003-03-0989 · DOI
- 10.1182/blood.V97.9.2777 · DOI
- Chen H, 2000, Blood, 96, 3181, 10.1182/blood.V96.9.3181 · DOI
- 10.1182/blood-2003-08-2763 · DOI
- 10.1080/10428190290011921 · DOI
- 10.1182/blood-2002-04-1174 · DOI
- 10.1016/S0065-230X(00)79005-1 · DOI
- 10.1182/blood-2001-11-0066 · DOI
- Schiffer LM, 1969, Br J Haematol, 17, 408
- Theml H, 1973, Blood, 42, 623, 10.1182/blood.V42.4.623.623 · DOI
- 10.1038/sj.bjc.6600763 · DOI
- 10.1182/blood-2003-04-1345 · DOI
- 10.1073/pnas.022604399 · DOI
- 10.1016/S0161-5890(01)00025-6 · DOI
- 10.1126/science.286.5447.2156 · DOI
- 10.1084/jem.190.10.1405 · DOI
- 10.1172/JCI113620 · DOI
- 10.1006/jaut.1993.1066 · DOI
- Pugh-Bernard AE, 2001, J Clin Invest, 108, 1061, 10.1172/JCI200112462 · DOI
- 10.1182/blood.V100.2.635 · DOI
- 10.1182/blood-2003-09-3277 · DOI
- 10.1182/blood-2002-03-0892 · DOI
- 10.1182/blood.V99.11.4087 · DOI
- 10.1016/S0952-7915(00)00204-1 · DOI
- 10.1084/jem.20031550 · DOI
- 10.1016/S1471-4906(03)00119-4 · DOI
Cited by
Immunity, Inflammation, and Cancer
Grivennikov, S. I., Greten, F. R., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.025 · Cited by 10,755
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
Byrd, J. C., Furman, R. R., Coutre, S. E., Flinn, I. W., Burger, J. A., Blum, K. A., Grant, B., Sharman, J. P., Coleman, M., Wierda, W. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215637 · Cited by 2,270
Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
Woyach, J. A., Furman, R. R., Liu, T.-M., Ozer, H. G., Zapatka, M., Ruppert, A. S., Xue, L., Li, D. H.-H., Steggerda, S. M., Versele, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1400029 · Cited by 1,275
ZAP-70: an essential kinase in T-cell signaling
Wang, H., Kadlecek, T. A., Au-Yeung, B. B., Goodfellow, H. E. S., Hsu, L. Y., Freedman, T. S., & Weiss, A. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a002279 · Cited by 395
Kaji, T., Ishige, A., Hikida, M., Taka, J., Hijikata, A., Kubo, M., Nagashima, T., Takahashi, Y., Kurosaki, T., Okada, M., et al. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20120127 · Cited by 263
Colonna-Romano, G., Bulati, M., Aquino, A., Pellicanò, M., Vitello, S., Lio, D., Candore, G., & Caruso, C. (2009) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2009.08.003 · Cited by 270
Himmelstein, D. S., & Baranzini, S. E. (2015) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1004259 · Cited by 172
Kaefer, A., Yang, J., Noertersheuser, P., Mensing, S., Humerickhouse, R., Awni, W., & Xiong, H. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2530-9 · Cited by 161
Evolution of ibrutinib resistance in chronic lymphocytic leukemia (CLL)
Komarova, N. L., Burger, J. A., & Wodarz, D. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1409362111 · Cited by 98
Metabolic plasticity in CLL: adaptation to the hypoxic niche
Koczula, K. M., Ludwig, C., Hayden, R., Cronin, L., Pratt, G., Parry, H., Tennant, D., Drayson, M., Bunce, C. M., Khanim, F. L., et al. (2016) · Leukemia · doi:10.1038/leu.2015.187 · Cited by 91
Characterization of ibrutinib-sensitive and -resistant mantle lymphoma cells
Ma, J., Lu, P., Guo, A., Cheng, S., Zong, H., Martin, P., Coleman, M., & Wang, Y. L. (2014) · British Journal of Haematology · doi:10.1111/bjh.12974 · Cited by 90
Aberrant LPL expression, driven by STAT3, mediates free fatty acid metabolism in CLL cells
Rozovski, U., Grgurevic, S., Bueso-Ramos, C., Harris, D. M., Li, P., Liu, Z., Wu, J. Y., Jain, P., Wierda, W., Burger, J., et al. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-14-0412 · Cited by 83
Inflammation and survival pathways: Chronic lymphocytic leukemia as a model system
Chen, L. S., Balakrishnan, K., & Gandhi, V. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.07.039 · Cited by 55
Troeger, A., Johnson, A. J., Wood, J., Blum, W. G., Andritsos, L. A., Byrd, J. C., & Williams, D. A. (2012) · Blood · doi:10.1182/blood-2011-12-395939 · Cited by 55
Involvement of RhoH GTPase in the development of B-cell chronic lymphocytic leukemia
Sanchez-Aguilera, A., Rattmann, I., Drew, D. Z., Müller, L. U. W., Summey, V, Lucas, D. M., Byrd, J. C., Croce, C. M., Gu, Y., Cancelas, J. A., et al. (2010) · Leukemia · doi:10.1038/leu.2009.217 · Cited by 52
Lanasa, M. C., Davis, P. H., Datto, M., Li, Z., Gockerman, J. P., Moore, J. O., DeCastro, C. M., Friedman, D. R., Diehl, L. F., Rehder, C., et al. (2012) · Leukemia & Lymphoma · doi:10.3109/10428194.2011.610012 · Cited by 16
Metadata
- Authors
- Chiorazzi, N., Rai, K. R., & Ferrarini, M.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-02-24
- Volume
- 352
- Issue
- 8
- Pages
- 804-815
- ISSN
- 0028-4793
- 1533-4406
- Cited by
- 1,296
- References
- 0
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
